French Maritime Pine Bark: Standardization, Dosing, and Safety

The single fact that governs this whole topic is that the studied extract is one standardized product — not a generic herb. Nearly all of the research was done on this one extract, standardized to 65–75% procyanidins, which means the studies do not automatically apply to other “pine bark extract” products. This page covers what standardization means, what is actually in the extract, how it is absorbed, the doses used in trials, its reassuring but not unlimited safety record, the drug interactions that matter (blood thinners, blood-pressure and diabetes drugs, surgery), pregnancy considerations, and an honest look at the industry-funding problem that runs through the whole literature.

One Standardized Extract, Not a Plant
What “Standardized” Means
The Evidence Is on This Extract
What Is Actually In It
Absorption and the Metabolite Story
How Much, How Often, How Long
Safety and Tolerability
Drug Interactions and Surgery
Pregnancy, Children, and Special Groups
The Industry-Funding Problem
Products, Labels, and Testing
Key Research Papers
External Resources
Connections
Featured Videos

One Standardized Extract, Not a Plant

Most supplements are named for a plant or nutrient — “turmeric,” “magnesium,” “fish oil.” The studied pine bark extract is different: most trials used a single standardized extract sold under a trademarked name (Pycnogenol); results may not transfer to other pine bark products. It is one specific, patented extract of the bark of the French maritime pine, Pinus pinaster, sourced from a single managed forest — the Landes de Gascogne in southwest France. The raw material, the extraction process, and the final composition are all controlled to a fixed specification.

This matters because products labeled “pine bark extract” are sold at a range of prices, and they are not necessarily the same thing: different pine species, different regions, different processing, and different procyanidin content. When a study reports that the extract “was shown to…,” the finding belongs to the standardized extract that was tested — and cannot simply be assumed for other pine bark products.

Back to Table of Contents

What “Standardized” Means

Plants are chemically variable. The same herb grown in two places, or harvested in two seasons, can differ several-fold in its active compounds. “Standardization” is the manufacturing practice of adjusting an extract so that every batch contains the same proportion of a chosen marker compound. The studied pine bark extract is standardized to 65–75% procyanidins (oligomeric proanthocyanidins, or OPCs).

Standardization is genuinely valuable: it is the reason researchers can compare studies and the reason the product is consistent from batch to batch. It also has limits. Standardizing to one class of marker does not guarantee that every minor component is identical, and it does not by itself prove effectiveness — it proves consistency. A consistent product that works is ideal; a consistent product still has to earn its clinical claims through trials, which brings us to the next point.

Back to Table of Contents

The Evidence Is on This Extract

Essentially all of the human research described across these Benefits pages — the venous, skin, and cardiovascular studies — used the same standardized pine bark extract. This is a real strength: unlike many herbs where studies used a hodgepodge of unstandardized preparations, here it is largely known what was tested. Rohdewald's (2002) review and Maimoona and colleagues' (2011) review both catalog this extract-specific body of work.

The flip side is a real gap in the evidence. Because the research is tied to one extract, the trial results have not been shown for generic “pine bark extract” products — a generic might be equivalent, weaker, or simply different in composition. The studied effects belong to the extract that was studied; other pine bark products may act as general-purpose antioxidants, but they are not backed by the same trials.

Back to Table of Contents

What Is Actually In It

The extract is a mixture, not a single molecule. Its main components are:

Procyanidins (OPCs), 65–75% — chains of the flavonoids catechin and epicatechin, of varying length. These are the headline actives and the same broad family found in grape seed extract, cocoa, and green tea.
Phenolic acids — including ferulic acid and caffeic acid, small, well-absorbed antioxidant molecules.
Taxifolin (dihydroquercetin) — a flavonoid related to quercetin.
Catechin and other monomers — single flavonoid units.

Packer and colleagues (1999) characterized the antioxidant chemistry of this procyanidin-rich mixture in detail. The practical takeaway is that the extract's effects probably come from the combination acting together, not from any one purified compound — which is another reason the specific standardized mixture, rather than an isolated ingredient, is what the science supports.

Back to Table of Contents

Absorption and the Metabolite Story

A fair question about any large polyphenol is whether the body actually absorbs it. Grimm and colleagues (2006) studied the pharmacokinetics of the standardized extract in healthy volunteers after single and repeated doses. The picture that emerged is nuanced: the small constituents (such as ferulic acid, catechin, and taxifolin) are absorbed fairly directly, while the larger procyanidins are only partly absorbed intact and are substantially transformed by gut bacteria into smaller molecules.

One of these bacterial metabolites — a valerolactone often abbreviated M1 — appears in the blood after dosing and is thought to carry some of the biological activity, meaning part of what the extract does may actually be done by compounds the gut microbiome makes from it. Repeated dosing produced accumulation of active constituents, consistent with daily intake. Two implications follow: individual gut microbiomes may cause person-to-person variation in response, and in studies it was generally taken with food, which is reported to aid tolerability and give steadier exposure.

Back to Table of Contents

How Much, How Often, How Long

Across the clinical literature, the extract has been used at roughly 50 to 360 mg per day, with most trials clustering around 100–200 mg per day. Trials commonly split it into two or three doses (for example, 50 mg two or three times daily), taken with or after meals. Rough patterns by use, based on the studies:

Venous insufficiency / edema: often 150–300 mg/day (see Circulation & Veins).
Cardiovascular / blood pressure: often 100–200 mg/day (see Blood Pressure & Heart).
Skin: often 50–100 mg/day (see Skin Health).

Effects build over weeks, not days; most studies ran four to twelve weeks. There is no established benefit to megadosing, and no evidence that more is better above the studied range. These figures describe what researchers used — they are not a personal prescription; decisions about doses, particularly alongside other medicines, belong with a clinician.

Back to Table of Contents

Safety and Tolerability

French maritime pine bark extract has a reassuring short-term safety record. Across many trials and both Cochrane reviews (Schoonees et al., 2012; Robertson et al., 2020), it was generally well tolerated, with adverse effects that were mild, infrequent, and similar to placebo. When side effects occur, the most common are:

Gastrointestinal upset (nausea, stomach discomfort) — reported to be less frequent when taken with food
Dizziness or headache
Occasional mouth ulcers or fatigue in a minority

Two honest limits belong alongside that reassurance. First, most safety data are short-term (weeks to a few months); long-term, everyday-use safety is less thoroughly documented. Second, “well tolerated in trials” describes the average participant — individuals can still react, and supplements are not required to meet the safety-testing standards of medicines. Overall, though, the tolerability profile is favorable.

Back to Table of Contents

Drug Interactions and Surgery

The interactions reported in the literature all flow from the extract's own mild pharmacology:

Blood thinners / antiplatelet drugs. Because the extract can reduce platelet stickiness, combining it with warfarin, apixaban, aspirin, clopidogrel, or similar drugs could theoretically increase bleeding risk; easy bruising or bleeding is the warning sign described, and this combination is one for medical supervision.
Blood-pressure medication. The extract can lower blood pressure slightly; on top of antihypertensives it may cause additive drops in readings.
Diabetes medication. It may lower blood glucose; combined with insulin or oral hypoglycemics, the concern is low blood sugar, and medication adjustments belong with a clinician.
Immune-modulating drugs. Because some studies suggest immune-stimulating activity, there is a theoretical concern with immunosuppressant therapy — a combination worth raising with a clinician.
Surgery. The commonly cited guidance is to stop the extract at least one to two weeks before any planned surgery or dental procedure, because of the antiplatelet effect and blood-pressure interaction.

Most of these are theoretical cautions rather than proven catastrophes, but the pattern — bleeding, blood pressure, blood sugar — is exactly where a “gentle” supplement can matter when stacked on real medication.

Back to Table of Contents

Pregnancy, Children, and Special Groups

Pregnancy and breastfeeding. A few studies used the extract in the second and third trimesters for venous problems and leg cramps without reported harm, but the overall safety data in pregnancy are limited, and there is little information for early pregnancy or breastfeeding. Because the pregnancy data are thin, it is not established as safe for use in pregnancy outside clinician-supervised care.

Children. The extract has been studied in children for specific conditions such as asthma (Lau et al., 2004) and attention-related concerns; in those studies use was clinician-supervised, and there is little evidence on unsupervised pediatric use.

Other groups. The research raises a concern for people with autoimmune conditions (given the theoretical immune-stimulating effect), bleeding disorders, or those on multiple medications, where individual questions belong with a clinician. As a general antioxidant supplement, the extract is not an established treatment for any diagnosed disease and has not been tested as a replacement for prescribed therapy.

Back to Table of Contents

The Industry-Funding Problem

No honest account of this extract can skip this. A large share of the clinical research has been funded by, or conducted in collaboration with, the manufacturer, and a substantial fraction comes from a single group of Italian investigators who have published many small studies using a similar registry-style design that is often not double-blinded or independently replicated. Independent systematic reviewers have repeatedly flagged this: the 2012 Cochrane review (Schoonees et al.) and the 2020 update on pine bark extract (Robertson et al.) both concluded that trials were generally small, heterogeneous, at risk of bias, and insufficient to draw firm conclusions for most conditions.

This does not mean the results are fabricated or that the extract does nothing — industry funds most supplement and drug research, and the mechanisms are real. It means the strength of the evidence is weaker than the volume of publications suggests, and that positive findings carry weight in proportion to their independence and rigor. The standout counterexample is Enseleit and colleagues' (2012) independent, double-blind coronary-artery-disease trial in the European Heart Journal, which is exactly the kind of study that carries more weight. More studies like that one are needed before any claim about the extract can be treated as settled.

Back to Table of Contents

Products, Labels, and Testing

A few facts about the products themselves and how the trials were run:

Products differ. The studied effects come from trials of one standardized extract; generic pine bark extracts, which vary in composition and price, are not backed by the same trials.
Labeled dose. Products list milligrams per serving; the ranges used in trials for each use are summarized above.
Third-party testing. Because supplements are lightly regulated, independent testing (for identity and contaminants) is the main outside check on what a product contains.
Time course. Trials measured real outcomes — leg swelling, blood pressure readings, skin hydration — over 8–12 weeks; effects, where seen, appeared on that timescale.
Medications and surgery. The interacting medications and planned surgery covered above are the situations where questions about this extract belong with a clinician.

Back to Table of Contents

Key Research Papers

Rohdewald P (2002). A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. International Journal of Clinical Pharmacology and Therapeutics — PubMed PMID: 11996210
Maimoona A et al. (2011). A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. Journal of Ethnopharmacology — PubMed PMID: 21044675
Grimm T et al. (2006). Single and multiple dose pharmacokinetics of maritime pine bark extract (Pycnogenol) after oral administration to healthy volunteers. BMC Clinical Pharmacology — PubMed PMID: 16887024
Packer L, Rimbach G, Virgili F (1999). Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Radical Biology and Medicine — PubMed PMID: 10490291
Schoonees A et al. (2012). Pycnogenol (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database of Systematic Reviews — PubMed PMID: 22513958
Robertson NU et al. (2020). Pine bark (Pinus spp.) extract for treating chronic disorders. Cochrane Database of Systematic Reviews — PubMed PMID: 32990945
Enseleit F et al. (2012). Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European Heart Journal — PubMed PMID: 22240497
Belcaro G et al. (2008). Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Report — PubMed PMID: 19017467
Lau BH et al. (2004). Pycnogenol as an adjunct in the management of childhood asthma. Journal of Asthma — PubMed PMID: 15641632
Devaraj S et al. (2002). Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids — PubMed PMID: 12530550
Stanislavov R et al. (2008). Improvement of erectile function with Prelox (Pycnogenol + L-arginine): a randomized, double-blind, placebo-controlled, crossover trial. International Journal of Impotence Research — PubMed PMID: 17703218